The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Data from a retrospective cohort study-Reference-Cited by-同舟云学术

The real-world treatment characteristic and efficacy of immune checkpoint inhibitors in non-small cell lung cancer: Data from a retrospective cohort study

Published:2024-06 Issue: Volume:134 Page:112152
ISSN:1567-5769
Container-title:International Immunopharmacology
language:en
Short-container-title:International Immunopharmacology

Author:

Zhang Chenyang^ORCID,Shao Jun,Tang Xiaolong,Wu Jiayang,Li Peiyi^ORCID,Li Weimin,Wang Chengdi^ORCID

Funder

Sichuan Province Science and Technology Support Program

West China Hospital of Sichuan University

Sichuan University

National Natural Science Foundation of China

Publisher

Elsevier BV

Reference51 articles.

1. The global burden of lung cancer: current status and future trends;Leiter;Nat. Rev. Clin. Oncol.,2023

2. National and subnational trends in cancer burden in China, 2005–20: an analysis of national mortality surveillance data;Qi;Lancet Public Health,2023

3. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2024

4. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment;Duma;Mayo Clin. Proc.,2019

5. The 2015 world health organization classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification;Travis;J. Thorac. Oncol.,2015

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Generation of Novel Tumour-Selective SEA Superantigen-Based Peptides with Improved Safety and Efficacy for Precision Cancer Immunotherapy;International Journal of Molecular Sciences;2024-08-30